Get the Stockscreener App
0.2918
10.24%
-0.0333
After Hours:
.29
-0.0018
-0.62%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Prophase Labs Inc stock is traded at $0.2918, with a volume of 1.80M.
It is down -10.24% in the last 24 hours and down -47.86% over the past month.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
See More
Previous Close:
$0.3251
Open:
$0.323
24h Volume:
1.80M
Relative Volume:
0.29
Market Cap:
$12.12M
Revenue:
$7.33M
Net Income/Loss:
$-21.20M
P/E Ratio:
-0.3192
EPS:
-0.9143
Net Cash Flow:
$-12.68M
1W Performance:
-24.31%
1M Performance:
-47.86%
6M Performance:
-11.76%
1Y Performance:
-86.68%
1-Day Range:
$0.2884
$0.323
1-Week Range:
$0.2884
$0.4206
52-Week Range:
$0.2179
$2.17
Prophase Labs Inc Stock (PRPH) Company Profile
Name
Prophase Labs Inc
Sector
Industry
Phone
(215) 345-0919
Address
711 STEWART AVE, SUITE 200, NEW YORK, PA
Compare PRPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRPH
Prophase Labs Inc
|
0.2918 | 13.51M | 7.33M | -21.20M | -12.68M | -0.9143 |
|
TMO
Thermo Fisher Scientific Inc
|
565.24 | 212.23B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
213.83 | 151.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.12 | 57.84B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
146.08 | 41.02B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.96 | 36.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Prophase Labs Inc Stock (PRPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-13-21 | Downgrade | Dawson James | Buy → Neutral |
| Jan-20-21 | Initiated | Dawson James | Buy |
Prophase Labs Inc Stock (PRPH) Latest News
How ProPhase Labs Inc. stock reacts to job market data2025 Technical Overview & Real-Time Stock Movement Alerts - newser.com
Using data filters to optimize entry into ProPhase Labs Inc.Trade Risk Report & Community Consensus Stock Picks - newser.com
How hedge fund analytics apply to ProPhase Labs Inc. stockEarnings Miss & Low Drawdown Trading Techniques - newser.com
Can machine learning forecast ProPhase Labs Inc. recoveryJuly 2025 Big Picture & Safe Entry Point Identification - newser.com
What moving averages say about ProPhase Labs Inc.CEO Change & AI Driven Price Predictions - newser.com
Is ProPhase Labs Inc. stock poised for growth2025 Major Catalysts & High Conviction Trade Alerts - newser.com
ProPhase Labs Inc. stock chart pattern explainedWeekly Profit Analysis & High Yield Stock Recommendations - newser.com
Why analysts upgrade ProPhase Labs Inc. stockGDP Growth & Step-by-Step Trade Execution Guides - newser.com
Using data tools to time your ProPhase Labs Inc. exit2025 Market Sentiment & Expert Verified Movement Alerts - newser.com
What data driven models say about ProPhase Labs Inc.’s futurePortfolio Performance Summary & Weekly Market Pulse Alerts - newser.com
ProPhase Labs Inc. stock retracement – recovery analysisTrade Risk Summary & Long-Term Capital Growth Ideas - newser.com
Can ProPhase Labs Inc. stock beat analyst upgradesMarket Risk Analysis & Fast Moving Trade Plans - newser.com
How strong is ProPhase Labs Inc. stock revenue growth2025 Major Catalysts & High Accuracy Trade Alerts - newser.com
PRPH proxy: digital‑asset charter, tokenized equity cap, split range - Stock Titan
Is ProPhase Labs Inc. building a consolidation baseWeekly Risk Summary & High Accuracy Buy Signal Tips - newser.com
ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology - The Manila Times
ProPhase (NASDAQ: PRPH) BE-Smart study shows 100% sensitivity; AUC 0.89 - Stock Titan
ProPhase Labs hires former Barstool Sports COO Stuart Hollenshead, plans cost-cutting measures - MSN
What technical signals suggest for ProPhase Labs Inc. stockJuly 2025 Price Swings & Safe Capital Investment Plans - fcp.pa.gov.br
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts - The Manila Times
ProPhase Labs (NASDAQ: PRPH) engages RedChip to lead investor relations: $50M target - Stock Titan
How ProPhase Labs Inc. stock reacts to inflationary pressures2025 Top Decliners & Low Risk Profit Maximizing Plans - Fundação Cultural do Pará
Prophase Labs Inc Stock (PRPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
6.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):